Arseus NV is a Belgium-based company that provides products, services and concepts for professionals and institutions active in the healthcare sector in Europe. Arseus is subdivided into four divisions and, among other things, is active in the markets for magisterial preparations for pharmacies, dental products, medical and surgical products and medical IT solutions. The Company distributes medical equipment and consumables in Belgium, Germany, Italy, The Netherlands, Switzerland, France, Spain, Czech Republic and the United Kingdom. Arseus NV is a part of the Omega Pharma Group and has various subsidiaries, including ABC Ducro Dental BV, Arseus Medical BV, Corilus BV, De Collegiale Bereiding BV and Fagron BV. 

http://www.arseus.com

Disclosure of acquisition of treasury shares 
Waregem (Belgium) / Rotterdam (Netherlands)*, April 7, 2010 - Arseus discloses the information with respect to the acquisition of treasury shares required under the new Article 207 of the Royal Decree of January 30, 2001 implementing the Belgian Company Code.
Arseus today announces that on March 31, it acquired 5,025 treasury shares on NYSE Euronext Brussels. Additionally, on March 30, 158 more shares were bought back on NYSE Euronext Brussels than stated in the press release of March 30, 2010.

Acquisition date  Number of shares  Average price  Lowest price  Highest price  Amount
30 March 2010
 158
 € 9.1289
 € 9.11
 € 9.24
 € 1,442

31 March 2010
 5,025
 € 9.1197 
 € 9.05 
 € 9.20 
 € 45,826 
 

The Extraordinary Shareholders' Meeting held on June 16, 2009 renewed the authorisation of the Board of Directors to acquire treasury shares.
For more information:
Constantijn van Rietschoten, Investor Relations Manager
+31 88 33 11 222 (Office)
+31 6 536 91 585 (Mobile)
constantijn.van.rietschoten@arseus.com
In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.

* This press release was sent out by Arseus NV and Arseus BV.

2009: An excellent year for Arseus 
NET PROFIT INCREASED 32% AT TURNOVER GROWTH OF 10%

STRUCTURAL IMPROVEMENT IN CASH FLOW (+42%)

Waregem (Belgium) / Rotterdam (Netherlands)[1], March 2, 2010

Key points 2009: 

Turnover growth of 10.3% to € 391.3 million 
REBITDA increases 10.7% to € 52.7 million
Net profit increases 31.8% to € 19.6 million 
Operational working capital decreases 170 basis points to 15.6% of turnover 
Cash flow from operating activities very strong: +42.4% to € 39.5 million 
Proposed dividend 2009: € 0.36 per share; an increase of 20% compared to 2008 
2010 outlook: Turnover growth of between 5% and 10% and a REBITDA that is expected to grow faster than turnover 
The Board of Directors appointed Sabine Sagaert, Mario Huyghe and Dirk Van Lerberghe to Arseus' Executive Committee 
Arseus is included in the Amsterdam Small Cap Index of NYSE Euronext as of March 2, 2010 

Ger van Jeveren, CEO of Arseus: "We can look back on an excellent year. Arseus proved resilient enough to deal with the challenging market conditions of 2009 and deliver excellent results. Our main focus has been the structural improvement of cash flow, resulting in an increase of 42%. Our healthy financial situation means we can further strengthen Fagron's leading market position in 2010 and consider add-on acquisitions for Arseus Dental, Arseus Medical and Corilus as suitable opportunities arise. Based on the current view and the existing portfolio, we are expecting turnover growth of between 5% and 10% in 2010 and a recurring EBITDA that is expected to grow faster than turnover."

[1] This press release was sent out by Arseus NV and Arseus BV.
 

Please open the link below for the full press release:

2009: An excellent year for Arseus